Understanding of the biology and clinical behavior of ductal carcinoma in situ (DCIS) is
currently inadequate. The aim of this comprehensive review was to identify important …

Context.—In situ carcinomas of the breast constitute 15% to 30% of all newly diagnosed
breast cancer cases; 80% of these in situ lesions belong to the ductal carcinoma in situ …

Abstract HOTAIR (HOX antisense intergenic RNA) is a long noncoding RNA (lncRNA) that is
transcribed from the antisense strand of homeobox C gene locus in chromosome 12 …

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression
at the post-transcriptional and/or translational level by binding loosely complimentary …

The type 1 tyrosine kinase receptor HER2 (c-erb B2/neu) is associated with resistance to
hormone therapy and poor survival in invasive breast cancer, whereas HER4 expression is …

Purpose: Ductal carcinoma in situ (DCIS) is thought to be a nonobligate precursor of
invasive cancer. Genomic changes specific to pure DCIS versus invasive cancer, as well as …

Purpose: Accurate testing of HER2 is centrally important for breast cancer therapy and
prognosis. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are …

OBJECTIVE.: The primary objective of this study was to determine the rate of response to
matuzumab in patients with recurrent, EGFR-positive ovarian, or primary peritoneal cancer …

Heterogeneous patterns of mutations and RNA expression have been well documented in
invasive cancers. However, technological challenges have limited the ability to study …

The roles of progesterone (P 4) and of progesterone receptor (PR) in development and
pathogenesis of breast cancer remain unclear. In this study, we observed that treatment of …